Kornimate/medical-research-clean huggingface dataset:
3d multi-contrast atherosclerosis characterization of the carotid artery

Conditions: Carotid Artery Disease

Summary: this is a technical development study with the goal to develop 3d techniques for atherosclerosis plaque characterization. we hypothesize that 3d mri is superior to 2d mri in characterizing major plaque constituents that contribute to severe clinical events such as myocardial infarction or stroke. the major advantages of the 3d techniques to be developed will include high spatial resolution, reduced scan times, and optimized image contrast. the use of contrast injection is not needed with the new techniques, which is greatly beneficial for patients with advanced chronic kidney disease.this is not a funded clinical trial.

all participants will undergo the conventional mri protocol and the new imaging protocol using our developed techniques. they may have either non-contrast scans or contrast-enhanced scans or both depending on the stage of development. the comparison results between the two protocols will be used to evaluate the performance of the new techniques and help optimization of specific technical aspects.

Eligibility criteria:
inclusion criteria: * healthy volunteers: male or female ≥ 18 years of age with a bmi\<30, with no history of cardiovascular disease * patients: medically stable, male or female ≥ 18 years of age diagnosed with an atherosclerotic plaque in the carotid artery who have not undergone stenting of the carotid artery to be imaged. * ability to read and understand informed consent exclusion criteria: * contraindications to mri including mechanically, magnetically, or electrically activated implants, ferromagnetic implants and ferromagnetic foreign bodies, pregnancy. * inability to tolerate mri secondary to an inability to lie supine or severe claustrophobia. * non-compliant with visit instructions, including inability to lie still, hold breath or follow procedure instructions * severe allergy to animal dander or animal-instigated asthma * specific to gadolinium-based contrast agents: renal function test does not meet csmc standard of care mri contrast protocol requirements (gfr \<45ml/min) or previous allergic reaction to gadolinium-based contrast agents.\*

Keywords: mri plaque characterization
systematic screening for primary immunodeficiencies in patients admitted for severe infection in pediatric intensive care unit

Conditions: Severe Infection; Severe Immune Deficiency

Summary: severe infections in pediatric intensive care unit are not uncommon. historically, the diagnosis of hereditary (primary) immune deficiency required a combination of recurrent clinical signs and biological stigmas. this paradigm is currently being questioned, and grows the hypothesis of a potential underlying genetic susceptibility in any severe infection. to date, the proportion of severe infections explained by an underlying immune deficiency is unknown. the aim of this prospective study is to assess the incidence of primary immune deficiencies in children with severe infection, regardless of their etiology.


Eligibility criteria:
inclusion criteria: * inclusion age less than 16 years * inclusion age \> 3 months of actual age for term infants and \> 3 months for former preterm infants. * documented severe infection (bacterial, viral, fungal) at the university hospital center of montpellier, toulouse or marseille * severe infections concerned by the study: any infection requiring hospitalization in pediatric intensive care (more than 24 hours) including: * meninges or brain lesions, pleuro-pneumopathy, any infection associated with sepsis and/or an opportunistic germ, septic shock, etc. * encephalitis and encephalomyelitis of infectious origin * child benefiting from a social security system * collection of parental/legal representative consent exclusion criteria: * undocumented severe infections * acute bronchiolitis * children admitted with isolated srv bronchiolitis without further complications from the infection; * previous comorbidity explaining the infection and/or stay in icu/continuing care: primary or known secondary immune deficiency; burns; risk factors for non-infectious epilepsy (encephalopathy, known epilepsy, head trauma), pneumonia caused by swallowing disorders or tracheotomy or chronic lung disease, asthma, meningitis favored by cochlear implants, breach of blood-brain barrier or neuromeningetic material, deep infection on implanted material or within 48h after surgery, cardiovascular decompensation; any other chronic conditions that may contribute to infection; * inability to obtain consent from parents/legal guardians.

Keywords: genetics screening
supportive care questionnaires in gathering data on unmet needs and health-related quality of life in latina breast cancer survivors after surgery, chemotherapy, or radiation therapy

Conditions: Breast Carcinoma; Cancer Survivor

Summary: this phase i/ii research trial studies supportive care questionnaires in gathering data on unmet needs and health-related quality of life in latina breast cancer survivors after surgery, chemotherapy, or radiation therapy. questionnaires that address unmet supportive care needs and health-related quality of life of breast cancer survivors may help doctors learn about barriers to cancer care that are linked to language, acculturation, knowledge about diagnosis and care, and financial concerns. learning about unmet needs of breast cancer patients may help increase quality of life and decrease healthcare utilization and costs.

primary objectives: i. to assess the supportive care needs and preferences of breast cancer survivors at los angeles county + university of southern california (usc) medical center (lac+usc). secondary objectives: i. to determine the lifestyle-related challenges of individuals with breast cancer being treated at lac+usc. ii. to determine the communication and healthcare delivery style needs and preferences of individuals with breast cancer being treated at lac+usc. outline: participants complete the demographic questionnaire, supportive care needs survey (scns)-34, 36-item short form health survey (sf-36), and the lifestyle needs survey. within 1 year of completing questionnaires, some participants may complete a one-hour in-person one-on-one interview comprising questions about the challenges and experiences of cancer survivorship, their health and well-being, and supportive care needs.

Eligibility criteria:
inclusion criteria: * patients receiving ongoing care, including routine follow-up, at lac+usc * diagnosis of breast cancer * completed primary surgical treatment, chemotherapy, and/or radiation * ability to understand and the willingness to sign a written informed consent exclusion criteria: * inability to sign written informed consent or to complete questionnaires/surveys * diagnosis of metastatic cancer
anxiety in non-professional football players with recurrent hamstring injuries.

Conditions: Football Player

Summary: introduction. faced with the risk of injury relapse, and as athletes train and compete, they generate anxiety that limits their ability to push themselves to the maximum, influencing their performance. objectives. i) to identify the state and trait anxiety of non-professional athletes with previous hamstring injuries; ii) to evaluate the main prognostic factors of anxiety in these athletes; and iii) to analyze the best predictive model of anxiety in soccer players with previous hamstring injuries. material and method. ambispective cross-sectional cohort study. 88 players will be recruited. the primary variable of the study will be anxiety (state-trait anxiety inventory), with the number of recurrences of the study injury being the dependent variable. the secondary variables, estimated as modifying or confounding, will be the main sociodemographic variables (age, type of school/work activity), clinical (number of hamstring injuries, number of relapses of injury in the same location, duration of injury in weeks, date of last injury), sports (weekly training load, seasons competing, regular starting line-up) and anthropometric (weight).


Eligibility criteria:
inclusion criteria: * male athletes aged 18 to 19 * registered in the division of honor category of the region of murcia * who are university students * with previous hamstring injuries in the last 12 months. exclusion criteria: * athletes with an injury, muscular or not, at the time of the study * athletes in their first year as registered soccer players.

Keywords: football players anxiety hamstring muscles recurrence of injury physiotherapy
effect of primidone on platelet responsiveness in patients determined to be clopidogrel resistant

Conditions: Clopidogrel Resistance; Secondary Stroke Prevention

Summary: the purpose of this study is to determine whether adding primidone will improve the metabolism of clopidogrel thereby increasing metabolite levels within the blood stream and platelet response to clopidogrel in patients who were previously found to lack adequate response to clopidogrel. this information could help overcome clopidogrel resistance in patients who are at risk for stroke or transient ischemic attack (tia).


Eligibility criteria:
inclusion criteria: * males and females aged 18 - 90 years who are clopidogrel resistant as determined by whole blood aggregometry * patients with a low risk of new cerebrovascular ischemic events as indicated by an essen stroke risk score of less than three exclusion criteria: * any history of allergy or intolerance to either plavix or clopidogrel * any history of allergy or intolerance to either mysoline or primidone * any clinically significant abnormalities in complete blood count as determined by the investigator * use of any acute medications within the last two weeks or initiation of any non-study medications during the study period that would effect cyp enzymes or platelet function * use of tobacco products from 2 weeks prior to enrollment in the study and throughout the duration of the study * any planned surgical procedures during the study or 5 days after the study has ended * history of alcoholism or alcohol abuse * participants who have had any alcohol consumption within 24 hours of a blood draw * previous stroke in past 3 months * participants who are or are planning to become pregnant * participants who of reproductive potential must agree to use a method of contraception for the duration of the study as well as 4 weeks after participation is complete * change in any medications that could affect liver enzymes or platelet aggregation throughout the study * compliance less than 80 % based on pill counts on two different study visits

Keywords: clopidogrel clopidogrel resistance primidone secondary stroke prevention
fenofibrate and metformin fixed combination vs metformin - fame metfo

Conditions: Dyslipidemia/Glucose Metabolism Disorder

Summary: to demonstrate in patients with t2dm and dyslipidemia not appropriately controlled with a statin and receiving metformin, the superiority of a fixed combination of fenofibrate and metformin vs metformin alone on tg and additionally, if the superiority on tg is established, to demonstrate the superiority on hdl-c


Eligibility criteria:
inclusion criteria patient with type 2 diabetes treated with stable dose of metformin and with dyslipidemia not appropriately controlled with a statin treatment. exclusion criteria type 1 diabetes.

Keywords: treatment of dyslipidemia and of type 2 diabetes mellitus
descemet membrane endothelial keratoplasty vs. descemet's stripping with endothelial keratoplasty vs. descemet stripping only

Conditions: Cystoid Macular Edema; Fuchs Dystrophy

Summary: this study aims to evaluate and compare incidence of post-operative cystoid macular edema (cme) after descemet membrane endothelial keratoplasty (dmek), descemet's stripping automated endothelial keratoplasty (dsek) and descemet stripping only (dso).

patients that are undergoing any of these procedures will be asked if they are willing to have a baseline pre-operative optical coherence tomography (oct) scan completed within 4 weeks of surgery. additional oct scans will be collected during routine follow up care. it is hypothesized that the rates of cme will be lower with dso compared to dmek and dsek.

Eligibility criteria:
inclusion criteria: * any patient that is undergoing dso or endothelial corneal transplantation vis dmek or dsek exclusion criteria: * patients that do not have an optical coherence tomography measurement pre- operatively * patients that don't have an optical coherence tomography measurement post- operatively * patients with a previous history of uncontrolled macular edema

Keywords: endothelial transplants endothelial dysfunction
vitality trial - sampling examination data

Conditions: Cardiac Event

Summary: this study´s aim is to collect data of vitality diagnosis. a cardiac ultrasound examination will be done and the data will be compared to the other examinations.


Eligibility criteria:
inclusion criteria: * mri exmination outcome: positive late enhancement, proof of infarction scars by contrast agent. exclusion criteria: * no exclusion criteria as patients are asked to participate after evaluating the mri examination outcome

Keywords: cardiac ultrasound vitality data patients examined
a novel strategy for personalized long-term dual antiplatelet therapy (rapid extend pilot study)

Conditions: Stable Coronary Syndrome; Percutaneous Coronary Intervention; Antiplatelet Therapy; Ticagrelor

Summary: in patients with heart attacks, the current standard of care is to restore blood flow through percutaneous coronary intervention (pci). this is done using stents (metal meshes) that opens up blockages. following pci, standard preventative drug treatment includes the use of dual antiplatelet therapy (dapt) using both aspirin and a platelet p2y12 receptor inhibitor (ticagrelor 90 mg twice a day or clopidogrel 75 mg once a day) for one year to prevent clotting that can result in additional heart attacks, sudden clotting of stents or death. new studies have shown that there is a benefit to continuing dapt beyond this one year mark. longer-term dapt has been shown to reduce ischemic events (heart attack, stroke) but increase the risk of bleeding. present guidelines state that the decision to continue dapt beyond the one year mark should be made on an individualized basis. the present study is a "pilot study" that seeks to compare long-term use of ticagrelor (ltt) versus a personalized approach (pa). we will be recruiting patients who have been stable (free of ischemic or bleeding outcomes) on dapt for 1 year after initial presentation with a heart attack. the pa group will use a modified dapt score based on patient demographics to decide whether treatment is warranted. patient will also undergo bedside genetic testing to identify potential at-risk genes. those identified as carriers will be treated with ticagrelor while non-carriers will be treated with clopidogrel. the present study will determine whether a personalized approach will decrease bleeding versus an approach of universal ticagrelor use. the hypothesis is that patients receiving a personalized strategy will have a decreased risk of bleeding.


Eligibility criteria:
inclusion criteria: * non-st-elevation myocardial infarction (nstemi) or st-elevation myocardial infarction (stemi) at presentation for index pci who have successfully completed \>1-year follow-up of rapid manage or tailor-pci trials without having incurred an ischemic or bleeding outcome while on dapt * patients with dapt interruption after 1 year will be eligible, if within 3 years of index mi patients must also have 1 of the following atherothrombotic risk enrichment criteria: * age ≥ 65 years * diabetes * 2nd prior mi (\> 1 year ago) * multi-vessel coronary disease * creatinine clearance \< 60ml/min exclusion criteria: patients will be excluded from the study if they: * refuse consent * are \> 3 years post mi * are deemed to require a p2y12 inhibitor * require oral anticoagulation * have a history of stroke, transient ischemic attack (tia) or intracranial bleed * have had a recent gi bleed or major surgery * have a life expectancy of \< 1 year * have a platelet count \< 100,000/μl * have a bleeding diathesis * have hematocrit \ 52% * are on dialysis or have severe liver disease * are at risk for bradycardia
the efficacy of tamsulosin in the treatment of ureteral stones in emergency department patients

Conditions: Kidney Stones; Ureteral Stones

Summary: to determine if emergency department patients with acute ureteral colic pain due to a ureteral stone who are treated with tamsulosin, versus placebo, will experience a shorter time to passage of their stone or resolution of their pain. a secondary study objective will be to determine if there is a relationship between response to tamsulosin and stone size or position in the ureter.

this is a prospective randomized placebo controlled study of tamsulosin alone, vs placebo, to determine its effect on the rates of stone passage and resolution of pain in patients with acute renal colic pain that present to the emergency department. the study will be conducted in the emergency department (ed)and emergency department observation unit (edou) of william beaumont hospital, a high volume, university affiliated 952 bed suburban teaching hospital. patients will be given a seven-day supply of tamsulosin (0.4mg daily) or placebo. they will also be given a prescription for vicodin (30 pills) and ibuprofen (600mg, 30 pills). they will be called on days 1, 2, 3, 7, and 10 following the index visit regarding passage of stone or 48 hours without pain. patients will be asked to call in if they pass their stone or are without pain for 48 hours. related return visits to royal oak or troy beaumont within 30 days of their index visit will be followed by chart review. the study will be limited to patients presenting to the emergency department with acutely symptomatic renal colic pain. confirmation of a symptomatic stone will be made by imaging (helical ct scan or intravenous pyelogram). study exclusion criteria: * stone not documented on imaging * stones \>10mm * pregnancy * age \<18 years * evidence of infection with an obstructing stone * obstructing stone in a solitary kidney * currently taking tamsulosin, vardenafil, nifedipine, or steroids * contraindications or allergy to tamsulosin * ureteral surgery * patients that are unable to understand consent * patients that are unable to comply with follow-up

Eligibility criteria:
inclusion criteria: * emergency department patients with acutely symptomatic renal colic pain * confirmation of a symptomatic stone will be made by imaging (helical ct scan or intravenous pyelogram). exclusion criteria: * stones not documented on imaging * stones \>10mm * pregnancy * age \<18 years * evidence of infection with an obstructing stone * obstructing stone in a solitary kidney * currently taking tamsulosin, vardenafil, nifedipine, or steroids * contraindications or allergy to tamsulosin * ureteral surgery * patients that are unable to understand consent * patients that are unable to comply with follow-up

Keywords: kidney stones ureteral stones flomax emergency medicine urology
irinotecan, 5-fluorouracil and leucovorin with or without iressa in the treatment of metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: the aim of the study is to determine if iressa added to chemotherapy with irinotecan, 5fluorouracil and leucovorin can prolong the period of time without any disease worsening (time to progression) in patients with metastatic colorectal cancer.


Eligibility criteria:
inclusion criteria: * histologically confirmed metastatic colorectal cancer * presence of measurable metastases * no previous treatment for metastatic cancer exclusion criteria: * no presence of central nervous system metastases * no other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ * any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease)

Keywords: metastatic colorectal cancer
hbv-specific t-cell immunity in individuals with hiv/hbv co-infection

Conditions: HIV; Hepatitis-B

Summary: the trial will randomise hiv/hbv co-infected individuals to different hbv-active antiretroviral therapy treatment regimens.

longitudinal study of circulating and intra-hepatic hbv-specific t-cell immunity in the setting of a randomised, controlled, international, multi-centre outpatient trial. the trial will randomise hiv/hbv co-infected individuals to different hbv-active antiretroviral therapy treatment regimens. study population: patients with hiv/hbv co-infection who are naive to hiv/hbv therapy, have detectable hbv viremia and are willing to start antiretroviral therapy.

Eligibility criteria:
inclusion criteria: * hiv positive * hepatitis-b co-infected * hbv/hiv therapy naive * \>18 years of age exclusion criteria: unable to sign consent form.

Keywords: hiv infection hepatitis coinfection
safety and pharmacology study of snx-5422 in subjects with refractory solid tumor malignancies

Conditions: Cancer

Summary: hsp90 is a chemical in the body that is involved in promotion of cancer. snx-5422 is an experimental drug that blocks hsp90. it is being evaluated for safety in patients with cancer.

correlation has been observed between hsp90 client protein level changes and functional effects in cells in in vitro studies of snx-5422, supporting inhibition of hsp90 as the mechanism of action for this compound. snx-5422 has demonstrated significant antitumor activity in mouse xenograft models of human tumors, including breast (bt474, mx-1), colon (ht29), prostate (pc3), and melanoma (a375) with multiple oral dosing regimens. this study will employ critical risk management features including the use of the nci common terminology criteria for adverse events (ctcae) version 4.03, which provides a scale for consistently grading the severity of aes, toxicity criteria analyses for dose escalation, frequent laboratory and clinical observations, correlation of aes with plasma concentrations of drug, monitoring of the qtc interval at appropriate time points, and a conservative dose-escalation scheme.

Eligibility criteria:
inclusion criteria: * \>18 years old histologically confirmed solid tumor malignancy refractory to available therapy or for which no therapy is available adequate organ function exclusion criteria: * cns malignancy significant gi disease at risk for prolonged qt interval

Keywords: solid tumor malignancy hsp90